Opus Genetics has acquired the rights to develop two preclinical-stage AAV-based gene therapy product candidates for inherited retinal diseases from Iveric Bio, according to a company press release.
The gene therapy candidates will reportedly address bestrophin-1 (BEST1)-related inherited retinal diseases and rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP).
Iveric received an upfront payment of $500,000 and high single-digit percentage ownership of Opus under the terms of the deal, while Opus will take over the global research, development and commercialization of BEST1